Celcuity appoints Charles Romp to board of directors; brings commercial oncology expertise

Celcuity Inc.

Charles (Chip) R. Romp appointed to board, effective Feb 11, 2026; board size increased from 7 to 8.
Romp is CEO of Secura Bio, previously EVP Commercial at Seagen (sold to Pfizer), with 25+ years oncology experience.
He will receive $50k annual cash retainer, $100k annual equity award, and pro-rated grant of 215 restricted shares vesting by 2026 annual meeting or April 30.
Company notes preparation for potential approval and launch of gedatolisib later this year (HR+/HER2- advanced breast cancer).
Romp qualifies as independent under Nasdaq and SEC rules; no committee assignments yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.